TITLE

Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors

AUTHOR(S)
Rutkowski, Piotr; Przybył, Joanna; Zdzienicki, Marcin
PUB. DATE
February 2013
SOURCE
Molecular Diagnosis & Therapy;Feb2013, Vol. 17 Issue 1, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
On the basis of the recently published results of a clinical trial comparing 12 and 36 months of imatinib in adjuvant therapy for gastrointestinal stromal tumors (GISTs), which demonstrated clinical benefit of longer imatinib treatment in terms of delaying recurrences and improving overall survival, both the US Food and Drug Administration and the European Medicines Agency have updated their recommendations and approved 36 months of imatinib treatment in patients with v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT)-positive GISTs (also known as CD117-positive GISTs) at high risk of recurrence after surgical resection of a primary tumor. This article discusses patient selection criteria for extended adjuvant therapy with imatinib, different classifications of risk of recurrence, and assessment of the response to therapy.
ACCESSION #
85316799

 

Related Articles

  • Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal. Duffaud, F.; Salas, S.; Huyn, T.; Deville, J. L. // Clinical & Experimental Gastroenterology;2010, Vol. 3, p41 

    Mutations of the KIT gene are the molecular hallmark of most gastrointestinal stromal tumors (GISTs). GIST has become a model for targeted treatment of solid tumors, imatinib becoming the standard first-line treatment of these tumors in the advanced/metastatic phase. Because of the efficacy of...

  • Gastrointestinal Stromal Tumour of stomach -- A case report and the Role of Imatinib. Das, D. K.; Quah W. J. // International Journal of Pharmacy Teaching & Practices (IJPTP);Sep2012, Vol. 3 Issue 3, p283 

    Introduction: Gastrointestinal Stromal tumour (GIST) is relatively an uncommon tumour, accounting for <1% of all gastrointestinal tract (GIT) tumours. Surgical resection for resectable cases remains the mainstay treatment. However, imatinib and most recently sutinib has emerged as a vital care...

  • Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial. Doyon, C.; Sidéris, L.; Leblanc, G.; Leclerc, Y. E.; Boudreau, D.; Dubé, P. // International Journal of Surgical Oncology;2012, p1 

    Purpose. Proven efficacy of imatinib mesylate in gastrointestinal stromal tumour (GIST) has led to its use in advanced disease and, more recently, in adjuvant and neoadjuvant settings. The purpose of this study was to evaluate the optimal neoadjuvant imatinib duration to reduce the morbidity of...

  • Imatinib.  // Reactions Weekly;Sep2014, Vol. 1518 Issue 1, p97 

    An abstract of the article "Long-term survival after excision of a giant esophageal gastrointestinal stromal tumor with imatinib mesylate resistance: Report of a case," by S. Takeno and colleagues is presented.

  • Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis. Bischof, Danielle; Dodson, Rebecca; Jimenez, M.; Behman, Ramy; Cocieru, Andrei; Blazer, Dan; Fisher, Sarah; Squires, Malcolm; Kooby, David; Maithel, Shishir; Groeschl, Ryan; Gamblin, T.; Bauer, Todd; Karanicolas, Paul; Law, Calvin; Quereshy, Fayez; Pawlik, Timothy // Journal of Gastrointestinal Surgery;Jun2015, Vol. 19 Issue 6, p1022 

    Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Adjuvant imatinib therapy improves recurrence-free and overall survival following surgery for patients with high-risk GIST; however, the factors associated with use of...

  • Approval Summary: Imatinib Mesylate in the Adjuvant Treatment of Malignant Gastrointestinal Stromal Tumors. Cohen, Martin H.; Cortazar, Patricia; Justice, Robert; Pazdur, Richard // Oncologist;Mar2010, Vol. 15 Issue 3, p300 

    On December 19, 2008, the U.S. Food and Drug Administration approved imatinib mesylate tablets for oral use (Gleevec®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) for the adjuvant treatment of adult patients following complete gross resection of Kit+ (CD117+) gastrointestinal...

  • SKP2 High Expression, KIT Exon 11 Deletions, and Gastrointestinal Bleeding as Predictors of Poor Prognosis in Primary Gastrointestinal Stromal Tumors Lv, Ang; Li, Zhongwu; Tian, Xiuyun; Guan, Xiaoya; Zhao, Min; Dong, Bin; Hao, Chunyi // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Background and Aims: Considering the indication of adjuvant therapy, the recurrence risk for primary gastrointestinal stromal tumor (GIST) after surgery needs to be accurately estimated. However, current risk stratification schemes may still have room for improvement. This study seeks to analyze...

  • C-Kit-Negative Gastrointestinal Stromal Tumor in the Stomach. Ho Seok Seo; Ji Yeon Hyeon; Ok-Ran Shin; Han Hong Lee // Journal of Gastric Cancer;Dec2015, Vol. 15 Issue 4, p290 

    C-kit-negative gastrointestinal stromal tumors (GISTs) are uncommon, and there have been few reports about the diagnosis and treatment of c-kit-negative GISTs in the stomach. We report the case of a patient who was diagnosed with a huge and atypical GIST in the stomach. The GIST was completely...

  • Gastrointestinal stromal tumor: Role of surgery and immunotherapy. Bhatnagar, Sushmita N. // Journal of Indian Association of Pediatric Surgeons;Oct-Dec2010, Vol. 15 Issue 4, p148 

    Report of a gastrointestinal stromal tumor in an 11-year-old girl who presented with a large lump in the upper abdomen. After complete surgical excision and histopathology, postoperative immunotherapy with imatinib led to an excellent outcome and a tumor-free survival of 3 years.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics